This is a Phase 4, single center study conducted in mild-to moderate asthmatics.
..Date First Received: November 4, 2005
Last Updated: March 31, 2008
Verified by: IVAX Research LLC, March 2008
Clinical Trial Phase: Phase 4 | Start Date: September 2005
Overall Status: Completed
Estimated Enrollment: 34
Brief Summary
Condition Keyword(s):
Intervention(s):
This is a Phase 4, single center study conducted in mild-to moderate asthmatics.
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment
Detailed Clinical Trial Description
The study consists of 3 phases. There are 7 study visits.
Intervention(s) in this Clinical Trial
- Drug: QVAR
Outcome Measures for this Clinical Trial
Primary Measures
- High resolution Cat Scans
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- 18-65 years old
- Currently using SABA prn or a low-to-moderate persistent asthma
Exclusion Criteria:
- Tobacco use within 1 year or >= 5 pack years
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 65 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: IVAX Research LLC
Overall Clinical Trial Officials and Contacts
Michelle Zeidler, MD Principal Investigator University of California, Los Angeles
Additional Information
Information obtained from ClinicalTrials.gov on December 03, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00250341
Study ID Number: IXR-403-4-196
ClinicalTrials.gov Identifier: NCT00250341
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
